Anderson, James R

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

Long, G. V., Dummer, R., Hamid, O., Gajewski, T. F., Caglevic, C., Dalle, S., Arance, A., Carlino, M. S., Grob, J.-J., Kim, T. M., et al. (2019) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 960

A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study

Spunt, S. L., Million, L., Chi, Y.-Y., Anderson, J., Tian, J., Hibbitts, E., Coffin, C., McCarville, M. B., Randall, R. L., Parham, D. M., et al. (2020) · The Lancet Oncology

Sarcoma Diagnosis and TreatmentAcute Lymphoblastic Leukemia research

Cited by 183